»
IN BRIEF
DEUTSCHE BANK TO CREATE 700 NEW JOBS IN DUBLIN
Deutsche Bank is taking 100,000 sq ft of office space at Eastpoint Business Park, leading to the creation of 700 jobs in the coming years in Dublin, which the bank aims to make a regional hub and centre of excellence. With a presence in Dublin since 1991, Deutsche Bank employs over 300 people in the city. It intends to build on the successful business it has in the capital across group technology and operations and global transaction banking. Hiring will start in 2014.
The project is supported by the
Department of Jobs, Enterprise and Innovation, through IDA Ireland.
NEW €58M ‘AMBER’ RESEARCH CENTRE LAUNCHED
A €58m research centre focused on advanced materials and bio- engineering will support 99 highly- skilled jobs. The centre’s research
programme will translate science into new discoveries and devices for a range of sectors such as the development of the next generation computer chips and new medical implants and pharmaceuticals that will improve patient care. Called the Amber Research
Centre, it is funded by the Department of Jobs, Enterprise and Innovation through €35m in Science Foundation Ireland funding. This has been leveraged with an
additional €23m from 18 industry partners, including Intel, DePuy, Medtronic, Merck Millipore and SAB Miller.
PFIZER TO
INVEST
US$130M IN IRISH PLANTS
Pfizer is investing US$100m in its Grange Castle site in Dublin and US$30m in its Ringaskiddy site in Cork. According to the company, the
investments, which are supported by the Department of Jobs, Enterprise and Innovation through IDA Ireland, “will enable the sites to expand their capacity and begin producing more advanced, complex therapies to deal with some of the most devastating and difficult to cure diseases”. “We are seeing the benefits of the
investments we’ve been making in our innovative core, as evidenced by recent key launches of medicines for stroke prevention, rheumatoid arthritis and cancer, as well as significant progress within our mid-to-late stage product pipeline,” said Dr Paul Duffy, vice- president, Pfizer. “There is opportunity for Pfizer’s
Irish sites to attract the development of new medicines, while also continuing to manufacture existing, important medicines. “Over the last 45 years, Pfizer has
continued to innovate and transform its products to cater to the changing demands of its customers,” said IDA Ireland CEO Barry O’Leary. “The Ringaskiddy site was Pfizer’s first manufacturing facility in Ireland almost 45 years ago – it is fantastic to see the work at that site evolve into hi-tech manufacturing. “Since Pfizer first set up in Ireland
in the 1970s, it has invested more than US$7bn in developing the skills, scale and capability necessary to manufacture some of its leading medicines for global export from Ireland.’’ The Ringaskiddy investment will be used to develop new specialist capability to manufacture some of the company’s newest medicines in cancer and other future pipeline medicines.
10 INNOVATION IRELAND REVIEW Issue 7 Autumn/Winter 2013
Taoiseach Enda Kenny TD and Prof Don Barry, president, University of Limerick
€52M BERNAL PROJECT LAUNCHED AT UNIVERSITY OF LIMERICK
The recently launched Bernal Project, a €52m science and engineering initiative at the University of Limerick (UL), is intended to contribute to Ireland’s national research initiatives in the strategically important areas of pharmaceutical, biomedical and energy research and development. The project will involve the
recruitment of 10 leading professors, a start-up seed fund to support their teaching and research activity, and the construction of a new advanced research building on campus. The Bernal Laboratory will house
fully equipped laboratory facilities in a 7,459 sq metre building. The building project has begun with completion envisaged by 2015. “The imperative in growing the
university and contributing to the economic development of Ireland is premised on developing a deep knowledge infrastructure and human capital base that will attract investment and stimulate the development of high-end industry and services at the core of a revitalised smart economy,” said UL president Prof Don Barry. “This investment will have major
significance in promoting Ireland as a location for foreign direct investment and job creation particularly in R&D and advanced manufacturing,” said Dr Mary Shire, vice-president research, UL. The project is named after 20th
century Irish-born scientist John Desmond Bernal.
Dr Paul Duffy , vice-president, Pfizer
Page 1 |
Page 2 |
Page 3 |
Page 4 |
Page 5 |
Page 6 |
Page 7 |
Page 8 |
Page 9 |
Page 10 |
Page 11 |
Page 12 |
Page 13 |
Page 14 |
Page 15 |
Page 16 |
Page 17 |
Page 18 |
Page 19 |
Page 20 |
Page 21 |
Page 22 |
Page 23 |
Page 24 |
Page 25 |
Page 26 |
Page 27 |
Page 28 |
Page 29 |
Page 30 |
Page 31 |
Page 32 |
Page 33 |
Page 34 |
Page 35 |
Page 36 |
Page 37 |
Page 38 |
Page 39 |
Page 40 |
Page 41 |
Page 42 |
Page 43 |
Page 44 |
Page 45 |
Page 46 |
Page 47 |
Page 48 |
Page 49 |
Page 50 |
Page 51 |
Page 52 |
Page 53 |
Page 54 |
Page 55 |
Page 56 |
Page 57 |
Page 58 |
Page 59 |
Page 60 |
Page 61 |
Page 62 |
Page 63 |
Page 64 |
Page 65 |
Page 66 |
Page 67 |
Page 68 |
Page 69 |
Page 70 |
Page 71 |
Page 72 |
Page 73 |
Page 74 |
Page 75 |
Page 76 |
Page 77 |
Page 78 |
Page 79 |
Page 80